MOEXIPRIL: 23 Adverse Event Reports & Safety Profile
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
23
Total FAERS Reports
5 (21.7%)
Deaths Reported
12
Hospitalizations
23
As Primary/Secondary Suspect
Apr 19, 1995
FDA Approved
Chartwell RX, LLC
Manufacturer
Discontinued
Status
Yes
Generic Available
Active Ingredient: MOEXIPRIL HYDROCHLORIDE · Drug Class: Angiotensin Converting Enzyme Inhibitor [EPC] · Route: ORAL · Manufacturer: Chartwell RX, LLC · FDA Application: 020312 · HUMAN PRESCRIPTION DRUG · FDA Label: Available
First Report: 20020106 · Latest Report: 20191029
What Are the Most Common MOEXIPRIL Side Effects?
#1 Most Reported
Drug hypersensitivity
5 reports (21.7%)